Citigroup’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $570K | Sell |
26,396
-5,862
| -18% | -$127K | ﹤0.01% | 3466 |
|
|
2025
Q4 | $769K | Sell |
32,258
-4,506
| -12% | -$91.9K | ﹤0.01% | 3307 |
|
|
2025
Q3 | $500K | Sell |
36,764
-192,534
| -84% | -$2M | ﹤0.01% | 3577 |
|
|
2025
Q2 | $1.87M | Buy |
229,298
+19,376
| +9% | +$166K | ﹤0.01% | 2706 |
|
|
2025
Q1 | $1.65M | Buy |
209,922
+103,227
| +97% | +$1.2M | ﹤0.01% | 2876 |
|
|
2024
Q4 | $1.59M | Buy |
106,695
+40,739
| +62% | +$665K | ﹤0.01% | 2991 |
|
|
2024
Q3 | $1.01M | Buy |
65,956
+18,303
| +38% | +$289K | ﹤0.01% | 3256 |
|
|
2024
Q2 | $726K | Sell |
47,653
-268,474
| -85% | -$4.33M | ﹤0.01% | 3132 |
|
|
2024
Q1 | $5.97M | Buy |
316,127
+188,896
| +148% | +$3.27M | ﹤0.01% | 1586 |
|
|
2023
Q4 | $2.43M | Sell |
127,231
-18,498
| -13% | -$296K | ﹤0.01% | 2073 |
|
|
2023
Q3 | $2.62M | Buy |
145,729
+25,083
| +21% | +$504K | ﹤0.01% | 1817 |
|
|
2023
Q2 | $2.45M | Sell |
120,646
-231,290
| -66% | -$4.4M | ﹤0.01% | 2017 |
|
|
2023
Q1 | $6.42M | Buy |
351,936
+225,255
| +178% | +$4.31M | ﹤0.01% | 1357 |
|
|
2022
Q4 | $2.62M | Sell |
126,681
-108,002
| -46% | -$2.97M | ﹤0.01% | 1844 |
|
|
2022
Q3 | $6.14M | Buy |
234,683
+56,183
| +31% | +$1.49M | ﹤0.01% | 1435 |
|
|
2022
Q2 | $4.52M | Buy |
178,500
+145,896
| +447% | +$3.57M | ﹤0.01% | 1590 |
|
|
2022
Q1 | $1.03M | Sell |
32,604
-76,296
| -70% | -$2.56M | ﹤0.01% | 2926 |
|
|
2021
Q4 | $4.41M | Buy |
108,900
+46,415
| +74% | +$1.8M | ﹤0.01% | 1935 |
|
|
2021
Q3 | $2.18M | Sell |
62,485
-100,784
| -62% | -$3.14M | ﹤0.01% | 2479 |
|
|
2021
Q2 | $4.48M | Buy |
163,269
+45,873
| +39% | +$1.31M | ﹤0.01% | 1990 |
|
|
2021
Q1 | $3.3M | Buy |
117,396
+93,878
| +399% | +$3.27M | ﹤0.01% | 2123 |
|
|
2020
Q4 | $611K | Buy |
23,518
+15,972
| +212% | +$387K | ﹤0.01% | 4025 |
|
|
2020
Q3 | $129K | Sell |
7,546
-18,875
| -71% | -$422K | ﹤0.01% | 4927 |
|
|
2020
Q2 | $654K | Buy |
26,421
+16,812
| +175% | +$454K | ﹤0.01% | 3983 |
|
|
2020
Q1 | $133K | Buy |
9,609
+24
| +0.3% | +$298 | ﹤0.01% | 5101 |
|
|
2019
Q4 | $97K | Buy |
9,585
+2,231
| +30% | +$18.8K | ﹤0.01% | 5799 |
|
|
2019
Q3 | $67K | Sell |
7,354
-3,689
| -33% | -$29.6K | ﹤0.01% | 5947 |
|
|
2019
Q2 | $88K | Sell |
11,043
-232
| -2% | -$2.32K | ﹤0.01% | 5988 |
|
|
2019
Q1 | $141K | Sell |
11,275
-120
| -1% | -$1.3K | ﹤0.01% | 5434 |
|
|
2018
Q4 | $122K | Buy |
11,395
+5,824
| +105% | +$68K | ﹤0.01% | 5487 |
|
|
2018
Q3 | $78K | Buy |
5,571
+1,757
| +46% | +$22.4K | ﹤0.01% | 6133 |
|
|
2018
Q2 | $47K | Buy |
3,814
+814
| +27% | +$12.8K | ﹤0.01% | 6342 |
|
|
2018
Q1 | $46K | Buy |
+3,000
| New | +$50K | ﹤0.01% | 6224 |
|
Other funds holding RCUS
GS
SCM
VPM
VCM
WP
SL
Citigroup's RCUS Position: Q1 2026 in Review
Citigroup reduced its Arcus Biosciences (RCUS) stake by 18% in Q1 2026, selling an estimated $127K and leaving 26,396 shares worth $570K. The position accounts for ﹤0.01% of the portfolio, ranked #3466.
Citigroup first reported a position in RCUS in Q1 2018 and has held it in 33 quarters since. The position peaked at $6.42M in Q1 2023. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.
- Citigroup held 26,396 shares of Arcus Biosciences worth $570K as of Q1 2026.
- Citigroup sold 5,862 Arcus Biosciences shares in Q1 2026, an estimated $127K.
- Arcus Biosciences made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3466 holding.
- Citigroup first reported a position in Arcus Biosciences in Q1 2018 and has held it in 33 quarters since.
- Citigroup's Arcus Biosciences position peaked at $6.42M in Q1 2023.
- 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.